KRAS and neoplasm: Thus, interfering with the PS exchange between the PM and the ER effectively depletes PS contents in the PM, compromises the nanoclustering and function of oncogenic mutant KRAS and specifically attenuates the tumor activities of the KRAS-dependent tumor cells.